Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
…, AS Moore, MD Norris, TN Trahair, RB Lock, V Tyrrell… - Nature medicine, 2020 - nature.com
The Zero Childhood Cancer Program is a precision medicine program to benefit children
with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline whole …
with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline whole …
[PDF][PDF] Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design
…, K Bendak, JW Böhm, GM Marshall, V Tyrrell… - Cell reports, 2019 - cell.com
Accelerating cures for children with cancer remains an immediate challenge as a result of
extensive oncogenic heterogeneity between and within histologies, distinct molecular …
extensive oncogenic heterogeneity between and within histologies, distinct molecular …
[HTML][HTML] Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile
fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical …
fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical …
[PDF][PDF] Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities
Pediatric solid and central nervous system tumors are the leading cause of cancer-related
death among children. Identifying new targeted therapies necessitates the use of pediatric …
death among children. Identifying new targeted therapies necessitates the use of pediatric …
[HTML][HTML] The rise of rapid implementation: a worked example of solving an existing problem with a new method by combining concept analysis with a systematic …
Background The concept of rapid implementation has emerged in the literature recently, but
without a precise definition. Further exploration is required to distinguish the concept’s …
without a precise definition. Further exploration is required to distinguish the concept’s …
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
…, A Fellowes, SB Fox, MD Norris, V Tyrrell… - EMBO molecular …, 2022 - embopress.org
Biomarkers which better match anticancer drugs with cancer driver genes hold the promise
of improved clinical responses and cure rates. We developed a precision medicine platform …
of improved clinical responses and cure rates. We developed a precision medicine platform …
[HTML][HTML] Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives
Background Paediatric precision oncology aims to match therapeutic agents to driver gene
targets. We investigated whether parents and patients regret participation in precision …
targets. We investigated whether parents and patients regret participation in precision …
Re-imagining the data collection and analysis research process by proposing a rapid qualitative data collection and analytic roadmap applied to the dynamic context …
…, TA O'Brien, S Smith, VJ Tyrrell… - International …, 2022 - journals.sagepub.com
Our implementation science study focuses on implementing a new way of practice and offers
methodological specificity about how to rapidly investigate an individually tailored precision …
methodological specificity about how to rapidly investigate an individually tailored precision …
[HTML][HTML] Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of …
…, MM Williams, PJ Wood, MJ Cowley, V Tyrrell… - Scientific reports, 2023 - nature.com
Diffuse midline gliomas (DMG) harbouring H3K27M mutation are paediatric tumours with a
dismal outcome. Recently, a new subtype of midline gliomas has been described with similar …
dismal outcome. Recently, a new subtype of midline gliomas has been described with similar …
[HTML][HTML] Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
…, M Wong, A Sherstyuk, GM Marshall, V Tyrrell… - NPJ Precision …, 2021 - nature.com
The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal,
with surgical resection being the only definitive salvage therapy. Treatment with …
with surgical resection being the only definitive salvage therapy. Treatment with …